SG Americas Securities LLC Has $1.37 Million Stake in Bruker Corporation $BRKR

SG Americas Securities LLC raised its position in shares of Bruker Corporation (NASDAQ:BRKR) by 199.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 42,293 shares of the medical research company’s stock after purchasing an additional 28,184 shares during the quarter. SG Americas Securities LLC’s holdings in Bruker were worth $1,374,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Nisa Investment Advisors LLC grew its holdings in shares of Bruker by 377.5% during the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after buying an additional 487 shares in the last quarter. Huntington National Bank lifted its stake in Bruker by 750.0% in the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock worth $30,000 after acquiring an additional 645 shares in the last quarter. Spire Wealth Management acquired a new stake in Bruker during the 2nd quarter worth about $32,000. Parallel Advisors LLC grew its stake in Bruker by 63.0% during the 2nd quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 347 shares in the last quarter. Finally, True Wealth Design LLC increased its holdings in shares of Bruker by 16,716.7% in the 2nd quarter. True Wealth Design LLC now owns 1,009 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 1,003 shares during the period. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Analyst Upgrades and Downgrades

BRKR has been the subject of several research reports. Wells Fargo & Company raised their price target on shares of Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. Wolfe Research raised shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 target price for the company in a research note on Wednesday, December 10th. Bank of America upped their price target on shares of Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Citigroup increased their price objective on Bruker from $40.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday. Finally, TD Cowen lifted their price objective on Bruker from $42.00 to $53.00 and gave the company a “hold” rating in a research report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Bruker has an average rating of “Hold” and a consensus target price of $53.36.

Bruker Price Performance

Shares of Bruker stock opened at $48.39 on Friday. The stock has a market capitalization of $7.35 billion, a price-to-earnings ratio of -302.44, a PEG ratio of 6.38 and a beta of 1.17. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $61.01. The company has a current ratio of 1.85, a quick ratio of 0.91 and a debt-to-equity ratio of 0.81. The firm has a fifty day simple moving average of $47.19 and a 200-day simple moving average of $40.06.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.12. The business had revenue of $860.50 million for the quarter, compared to analyst estimates of $847.40 million. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The firm’s revenue for the quarter was down .5% on a year-over-year basis. During the same period in the previous year, the company posted $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, sell-side analysts expect that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 2nd. Stockholders of record on Monday, December 8th were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. Bruker’s dividend payout ratio is currently -125.00%.

Insider Activity

In related news, Director John A. Ornell sold 6,233 shares of Bruker stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $39.00, for a total transaction of $243,087.00. Following the sale, the director directly owned 35,212 shares of the company’s stock, valued at $1,373,268. This trade represents a 15.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $49.20, for a total value of $98,400.00. Following the completion of the transaction, the vice president directly owned 128,443 shares of the company’s stock, valued at approximately $6,319,395.60. This trade represents a 1.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 15,233 shares of company stock valued at $726,487. 27.30% of the stock is owned by corporate insiders.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.